Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Blood Transfusion (for acute severe hemolysis)
Treatment for G6PD deficiency
Typical Dosage: Varies by patient's hemoglobin level and clinical status
Effectiveness
90%
Safety Score
65%
Clinical Trials
0
Participants
0
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Varies by patient's hemoglobin level and clinical status
Time to Effect
Immediate (within hours of administration)
Treatment Duration
As needed during acute hemolytic crisis (typically 1-2 units over several hours)
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$1,500
Side Effect Mgmt:$0
Total Annual:$1,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
5
Comparison vs No blood transfusion during severe crisis
Cost Difference
$0/year
Same cost
QALY Difference
+5.00 QALYs
Better outcomes
Dominance
No dominance
Blood Transfusion (for acute severe hemolysis) Outcomes
for G6PD deficiency
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+95%
Common Side Effects
Febrile non-hemolytic transfusion reaction
+1%
Allergic reaction
+0.5%
Delayed hemolytic transfusion reaction
+0.05%
Transfusion-associated circulatory overload (TACO)
+0.05%
Transfusion-related acute lung injury (TRALI)
+0.01%
Infection (e.g., HIV, HCV, HBV)
+0.0001%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov